BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33442657)

  • 1. Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features.
    Benefield HC; Reeder-Hayes KE; Nichols HB; Calhoun BC; Love MI; Kirk EL; Geradts J; Hoadley KA; Cole SR; Earp HS; Olshan AF; Carey LA; Perou CM; Troester MA
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
    Troester MA; Sun X; Allott EH; Geradts J; Cohen SM; Tse CK; Kirk EL; Thorne LB; Mathews M; Li Y; Hu Z; Robinson WR; Hoadley KA; Olopade OI; Reeder-Hayes KE; Earp HS; Olshan AF; Carey LA; Perou CM
    J Natl Cancer Inst; 2018 Feb; 110(2):176-82. PubMed ID: 28859290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.
    Albain KS; Gray RJ; Makower DF; Faghih A; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Wood WC; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW; Sparano JA
    J Natl Cancer Inst; 2021 Apr; 113(4):390-399. PubMed ID: 32986828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women.
    Benefield HC; Allott EH; Reeder-Hayes KE; Perou CM; Carey LA; Geradts J; Sun X; Calhoun BC; Troester MA
    J Natl Cancer Inst; 2020 Jul; 112(7):728-736. PubMed ID: 31742342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
    Sparano JA; Wang M; Zhao F; Stearns V; Martino S; Ligibel JA; Perez EA; Saphner T; Wolff AC; Sledge GW; Wood WC; Davidson NE
    J Natl Cancer Inst; 2012 Mar; 104(5):406-14. PubMed ID: 22250182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
    Lund MJ; Trivers KF; Porter PL; Coates RJ; Leyland-Jones B; Brawley OW; Flagg EW; O'Regan RM; Gabram SG; Eley JW
    Breast Cancer Res Treat; 2009 Jan; 113(2):357-70. PubMed ID: 18324472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
    Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
    BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of clinical, societal, and treatment variables on racial differences in ER-/PR- breast cancer survival.
    Roseland ME; Schwartz K; Ruterbusch JJ; Lamerato L; Krajenta R; Booza J; Simon MS
    Breast Cancer Res Treat; 2017 Aug; 165(1):163-168. PubMed ID: 28547656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial comparison of receptor-defined breast cancer in Southern African women: subtype prevalence and age-incidence analysis of nationwide cancer registry data.
    Dickens C; Duarte R; Zietsman A; Cubasch H; Kellett P; Schüz J; Kielkowski D; McCormack V
    Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2311-21. PubMed ID: 25143359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.
    Luyeye Mvila G; Batalansi D; Praet M; Marchal G; Laenen A; Christiaens MR; Brouckaert O; Ali-Risasi C; Neven P; Van Ongeval C
    Breast; 2015 Oct; 24(5):642-8. PubMed ID: 26279132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.
    Clarke CA; Keegan TH; Yang J; Press DJ; Kurian AW; Patel AH; Lacey JV
    J Natl Cancer Inst; 2012 Jul; 104(14):1094-101. PubMed ID: 22773826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
    Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
    J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.
    Keenan T; Moy B; Mroz EA; Ross K; Niemierko A; Rocco JW; Isakoff S; Ellisen LW; Bardia A
    J Clin Oncol; 2015 Nov; 33(31):3621-7. PubMed ID: 26371147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer.
    Pastoriza JM; Karagiannis GS; Lin J; Lanjewar S; Entenberg D; Condeelis JS; Sparano JA; Xue X; Rohan TE; Oktay MH
    Clin Exp Metastasis; 2018 Oct; 35(7):613-623. PubMed ID: 30136072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does race predict survival for women with invasive breast cancer?
    Walsh SM; Zabor EC; Stempel M; Morrow M; Gemignani ML
    Cancer; 2019 Sep; 125(18):3139-3146. PubMed ID: 31206623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Race and the prognostic influence of p53 in women with breast cancer.
    Dookeran KA; Dignam JJ; Holloway N; Ferrer K; Sekosan M; McCaskill-Stevens W; Gehlert S
    Ann Surg Oncol; 2012 Jul; 19(7):2334-44. PubMed ID: 22434242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of molecular subtype and race on HR+, HER2- breast cancer survival.
    Reid S; Haddad D; Tezak A; Weidner A; Wang X; Mautz B; Moore J; Cadiz S; Zhu Y; Zheng W; Mayer IA; Shu XO; Pal T
    Breast Cancer Res Treat; 2021 Oct; 189(3):845-852. PubMed ID: 34331630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women.
    Cui Y; Deming-Halverson SL; Shrubsole MJ; Beeghly-Fadiel A; Fair AM; Sanderson M; Shu XO; Kelley MC; Zheng W
    Clin Breast Cancer; 2014 Dec; 14(6):417-25. PubMed ID: 24970715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
    Lin NU; Vanderplas A; Hughes ME; Theriault RL; Edge SB; Wong YN; Blayney DW; Niland JC; Winer EP; Weeks JC
    Cancer; 2012 Nov; 118(22):5463-72. PubMed ID: 22544643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study.
    Parada H; Sun X; Fleming JM; Williams-DeVane CR; Kirk EL; Olsson LT; Perou CM; Olshan AF; Troester MA
    Breast Cancer Res; 2017 Dec; 19(1):131. PubMed ID: 29228969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.